Annual EBITDA
-$38.13 M
-$23.01 M-152.18%
December 31, 2023
Summary
- As of February 8, 2025, SABS annual EBITDA is -$38.13 million, with the most recent change of -$23.01 million (-152.18%) on December 31, 2023.
- During the last 3 years, SABS annual EBITDA has fallen by -$59.27 million (-280.43%).
- SABS annual EBITDA is now -280.43% below its all-time high of $21.14 million, reached on December 31, 2020.
Performance
SABS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.30 M
-$3.12 M-50.39%
September 30, 2024
Summary
- As of February 8, 2025, SABS quarterly EBITDA is -$9.30 million, with the most recent change of -$3.12 million (-50.39%) on September 30, 2024.
- Over the past year, SABS quarterly EBITDA has dropped by -$5.26 million (-129.90%).
- SABS quarterly EBITDA is now -609.11% below its all-time high of $1.83 million, reached on March 31, 2022.
Performance
SABS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$40.29 M
-$5.26 M-15.01%
September 30, 2024
Summary
- As of February 8, 2025, SABS TTM EBITDA is -$40.29 million, with the most recent change of -$5.26 million (-15.01%) on September 30, 2024.
- Over the past year, SABS TTM EBITDA has dropped by -$17.15 million (-74.14%).
- SABS TTM EBITDA is now -2386.39% below its all-time high of $1.76 million, reached on March 31, 2021.
Performance
SABS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SABS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -152.2% | -129.9% | -74.1% |
| 3 y3 years | -280.4% | -52.6% | -110.9% |
| 5 y5 years | -363.1% | -52.6% | -110.9% |
SABS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -152.2% | at low | -609.1% | +57.4% | -166.4% | at low |
| 5 y | 5-year | -280.4% | at low | -609.1% | +57.4% | -2386.4% | at low |
| alltime | all time | -280.4% | at low | -609.1% | +57.4% | -2386.4% | at low |
SAB Biotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.30 M(+50.4%) | -$40.29 M(+15.0%) |
| Jun 2024 | - | -$6.19 M(+108.7%) | -$35.03 M(+0.8%) |
| Mar 2024 | - | -$2.96 M(-86.4%) | -$34.76 M(-8.8%) |
| Dec 2023 | -$38.13 M(+152.2%) | -$21.83 M(+439.5%) | -$38.13 M(+64.8%) |
| Sep 2023 | - | -$4.05 M(-31.6%) | -$23.14 M(-8.1%) |
| Jun 2023 | - | -$5.91 M(-6.7%) | -$25.18 M(+8.1%) |
| Mar 2023 | - | -$6.34 M(-7.3%) | -$23.29 M(+54.0%) |
| Dec 2022 | -$15.12 M | -$6.84 M(+12.2%) | -$15.12 M(-20.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$6.10 M(+51.8%) | -$19.11 M(+15.2%) |
| Jun 2022 | - | -$4.02 M(-319.7%) | -$16.58 M(+9.6%) |
| Mar 2022 | - | $1.83 M(-116.9%) | -$15.13 M(-0.4%) |
| Dec 2021 | -$15.20 M(-171.9%) | -$10.82 M(+203.4%) | -$15.20 M(+247.5%) |
| Sep 2021 | - | -$3.57 M(+39.0%) | -$4.37 M(+443.2%) |
| Jun 2021 | - | -$2.57 M(-245.7%) | -$804.90 K(-145.7%) |
| Mar 2021 | - | $1.76 M | $1.76 M |
| Dec 2020 | $21.14 M(-356.7%) | - | - |
| Dec 2019 | -$8.23 M | - | - |
FAQ
- What is SAB Biotherapeutics annual EBITDA?
- What is the all time high annual EBITDA for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual EBITDA year-on-year change?
- What is SAB Biotherapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly EBITDA year-on-year change?
- What is SAB Biotherapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for SAB Biotherapeutics?
- What is SAB Biotherapeutics TTM EBITDA year-on-year change?
What is SAB Biotherapeutics annual EBITDA?
The current annual EBITDA of SABS is -$38.13 M
What is the all time high annual EBITDA for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual EBITDA is $21.14 M
What is SAB Biotherapeutics annual EBITDA year-on-year change?
Over the past year, SABS annual EBITDA has changed by -$23.01 M (-152.18%)
What is SAB Biotherapeutics quarterly EBITDA?
The current quarterly EBITDA of SABS is -$9.30 M
What is the all time high quarterly EBITDA for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly EBITDA is $1.83 M
What is SAB Biotherapeutics quarterly EBITDA year-on-year change?
Over the past year, SABS quarterly EBITDA has changed by -$5.26 M (-129.90%)
What is SAB Biotherapeutics TTM EBITDA?
The current TTM EBITDA of SABS is -$40.29 M
What is the all time high TTM EBITDA for SAB Biotherapeutics?
SAB Biotherapeutics all-time high TTM EBITDA is $1.76 M
What is SAB Biotherapeutics TTM EBITDA year-on-year change?
Over the past year, SABS TTM EBITDA has changed by -$17.15 M (-74.14%)